Does Patent Foramen Ovale Size Matter in Men and Women

Overview

A patent foramen ovale (PFO) is present in ~30% of the general population. The PFO has historically been considered to be trivial. However, recent work by the investigator's group and others has identified that, compared to individuals without a PFO, those with a PFO have worse pulmonary gas exchange efficiency, have a higher core body temperature, blunted ventilatory responses to chronic hypoxia and acute carbon dioxide and increased susceptibility to altitude illnesses such as acute mountain sickness, and high altitude pulmonary edema (Lovering, Elliott & Davis J Appl Physiol 2016). Specific to this application,subjects with a PFO may have worse pulmonary gas exchange efficiency because a PFO is a potential source of right-to-left shunt that will make pulmonary gas exchange efficiency worse. If true, then this may negatively impact exercise capacity and/or exercise tolerance. Further, in those with a PFO compared to those without, preliminary work from the investigator's lab indicates that there may be an effect of PFO size on pulmonary gas exchange efficiency. This is such that those with a large PFO (grade 3 or higher) display significantly worse gas exchange efficiency compared to those with a small (grade 2 or lower) or no PFO,even at low exercise workloads. Additionally, the investigators were curious as to whether there would be a sex effect, but due to logistical constraints, the investigators were unable to recruit an equal number of female and male subjects. Thus, in addition to the potential size effect on the investigators outcome measures, the investigators would like to build on this work by examining the potential effect of biological sex. Although a PFO has been traditionally considered to have a minimal impact of physiology and pathophysiology, emerging evidence suggests this may not be the case. The investigator's lab is focused on understanding how and why a relatively small hole in the heart (PFO) can have a relatively large impact on cardiopulmonary and respiratory physiology, and how these impacts may be based on the size of the PFO.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 31, 2022

Arms, Groups and Cohorts

  • No PFO
    • Research subjects who present no evidence of PFO – IE no appearance of saline contrast microbubbles within 3 cardiac cycles
  • Small PFO
    • Research subjects who present evidence of having a small PFO or ASD – IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
  • Large PFO
    • Research subjects who present evidence of having a large PFO – IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.

Clinical Trial Outcome Measures

Primary Measures

  • alveolar-arterial difference in oxygen
    • Time Frame: Baseline
    • difference in the partial pressure of oxygen between the alveoli (calculated) and arterial blood (direct measure)
  • aerobic exercise capacity
    • Time Frame: Baseline
    • ability to utilize oxygen while exercising, AKA Vo2MAX
  • six-minute walk test
    • Time Frame: Baseline
    • distance covered in 6 minutes of walking
  • minute flow of intrapulmonary areterio-venous anastamoses (QIPAVA)
    • Time Frame: Baseline
    • minute flow through intrapulmonary arteriovenous anastamoses
  • core body temperature
    • Time Frame: Baseline
    • subject’s core body temperature as measured through an ingestible pill
  • level of tumor necrosis factor alpha
    • Time Frame: Baseline
    • inflammatory marker
  • level of C-C motif cytokine 2
    • Time Frame: Baseline
    • inflammatory marker
  • level of interferon alpha 2
    • Time Frame: Baseline
    • inflammatory marker
  • level of interferon gamma
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 1 beta
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 6
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 8
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 10
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 12p70
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 17 alpha
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 18
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 23
    • Time Frame: Baseline
    • inflammatory marker
  • level of interleukin 33
    • Time Frame: Baseline
    • inflammatory marker
  • level of myoglobin
    • Time Frame: Baseline
    • inflammatory marker
  • level of myeloid-related protein 8/14
    • Time Frame: Baseline
    • inflammatory marker
  • level of neutrophil gelatinase-associated lipocalin
    • Time Frame: Baseline and 3 months post percutaneous closure
    • inflammatory marker
  • level of c-reactive protein
    • Time Frame: Baseline
    • inflammatory marker
  • matrix metallopeptidase 2
    • Time Frame: Baseline and 3 months post percutaneous closure
    • inflammatory marker
  • level of osteopontin
    • Time Frame: Baseline
    • inflammatory marker
  • level of myloperoxidase
    • Time Frame: Baseline
    • inflammatory marker
  • level of Serum amyloid A
    • Time Frame: Baseline
    • inflammatory marker
  • level of insulin like growth factor binding protein 4
    • Time Frame: Baseline
    • inflammatory marker
  • level of intracellular adhesion molecule 1
    • Time Frame: Baseline
    • inflammatory marker
  • level of vascular cell adhesion protein 1
    • Time Frame: Baseline
    • inflammatory marker
  • level of metallopeptidase 9
    • Time Frame: Baseline
    • inflammatory marker
  • level of Cystatin C
    • Time Frame: Baseline
    • inflammatory marker

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women aged 18-40 – Known to have/not have a PFO. Exclusion Criteria:

  • Previous history of coronary artery disease(ischemic heart disease such as angina, heart attack, myocardial infarction). – Failure of Modified Allen's Test in both hands. – Currently taking medications or herbal supplements for any heart or respiratory disease that they cannot stop taking for 48 hrsprior to testing (seasonal allergy medication not included in exclusion medications). – Lidocaine, nitroglycerine or heparin allergy. – Women who are pregnant or trying to become pregnant. – Previous history of any condition that would prevent the subject from performing cycle ergometer exercise (for exercise study only).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 40 Years

Investigator Details

  • Lead Sponsor
    • University of Oregon
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.